Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer

Molecularly targeted radiosensitization chances towards gene aberration-due organ confined/regionally advanced prostate cancer radioresistance

“…Among further developments of customized radiosensitizers, just those molecularly targeting the identified PCa cell radioresistance-linked individual gene aberrations will enhance the PCa radiation therapy lasting effectiveness (1)(2)(3)(4)(5)(6)(7)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19).…”

Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance

“…Indeed, given that individual cancer cell genome mutated exome sequencing gene identification and consequent targeting pharmacogenomic approaches result to be advantageous to improve conventional treatments outcomes, such personalized diagnostic and therapeutic measures -even by genome editing supply, possibly resorting to CRISPR-CAS9 technique -should be taken into consideration also in the field of current immunotherapy developments to particularly support the vaccination-induced anti-tumor immune response (97,100,101).…”